In general, when negative feedback is relieved in response to RAF, MEK, or ERK inhibitors, various RTKs are upregulated and activated (in cell- and context-dependent sets or combinations), which further activates RAS and causes ERK activity to recover, resulting in tumor adaptability, and inhibitor resistance. The gene discussed is MAP2K7; the disease is neoplasm.